Edition:
United States

Midatech Pharma PLC (MTP.OQ)

MTP.OQ on NASDAQ Stock Exchange Capital Market

1.06USD
8 Dec 2017
Change (% chg)

$0.01 (+0.95%)
Prev Close
$1.05
Open
$1.04
Day's High
$1.11
Day's Low
$1.04
Volume
1,658
Avg. Vol
2,131
52-wk High
$3.50
52-wk Low
$1.00

Summary

Name Age Since Current Position

Rolf Stahel

72 Non-Executive Chairman of the Board

James Phillips

Chief Executive Officer, Director

Nicholas Robbins-Cherry

45 Finance Director, Director

Craig Cook

2014 Chief Operating Officer / Chief Medical Officer

Daniel Palmer

Chief Scientific Officer

Justin Barry

Head - Manufacturing

Tim Sparey

Chief Business Officer

Simon De Vries

56 Non-Executive Director

John Johnston

Non-Executive Director

Michele Luzi

57 Non-Executive Director

Paul Protopapas

48 Non-Executive Director

Simon Turton

47 Senior Independent Non-executive Director

Biographies

Name Description

Rolf Stahel

Mr. Rolf Stahel is Non-Executive Chairman of the Board of Midatech Pharma PLC. Mr Stahel has approximately 40 years of experience in the pharmaceutical industry, of which around 20 years were spent at chief executive and board level in public companies listed in the United Kingdom, Switzerland and the United States and private life science companies registered in Europe, the United States and Asia. Mr. Stahel joined Shire as chief executive in 1994 following a 27-year career at Wellcome plc (now GlaxoSmithKline plc). Mr. Stahel is currently the non-executive chairman of Connexios Life Sciences Pvt Ltd and Ergomed PLC, and was previously the non-executive chairman of EUSA Pharma, Cosmos Pharmaceuticals SpA, PowderMed Ltd and Newron Pharmaceuticals SpA.

James Phillips

Dr. James (Jim) Neil Phillips, M.D., MBA, is Chief Executive Officer, Director of Midatech Pharma PLC. Dr Phillips has a strong background in company leadership and business development, and is a physician by training. Jim founded Talisker Pharma in 2004, which was the first and cornerstone acquisition of EUSA Pharma in 2006. As president of Europe and senior vice president, corporate development, of EUSA Pharma Inc., Dr Phillips led the strategy resulting in the acquisition of OPI and its ultimate acquisition by Jazz Pharmaceuticals in 2012. Jim is currently a non-executive director of Herantis Pharma PLC, listed in Helsinki, Insense Ltd, a private spin-out from Unilever, and, until joining Midatech, was chairman of Prosonix Limited, guiding its successful transformation into a respiratory-focused business. Dr Phillips initially held senior positions at Johnson & Johnson and Novartis Pharmaceuticals. At Novartis, Dr Phillips was in Clinical & Business Development and was a board director of the $1.3 billion arthritis, bone, gastrointestinal, haematology and infectious diseases business unit and a member of the company’s Clinical Leadership Team.

Nicholas Robbins-Cherry

Mr. Nicholas (Nick) John Robbins-Cherry, ACA, MBA is Finance Director, Director of Midatech Pharma PLC. Mr. Robbins-Cherry is a Chartered Accountant and MBA with extensive commercial and finance experience gained in the life sciences, technology and consulting sectors, including roles at CACI Limited, Johnson & Johnson and ICI PLC. Mr Robbins-Cherry has a strong track record in mergers and acquisitions and of managing complex multi-national businesses. Mr Robbins-Cherry qualified with Coopers & Lybrand (now PricewaterhouseCoopers) and also has a BSc in Pharmacology.

Craig Cook

Dr. Craig Cook, MBBCH, BSc (Hons), DA, MBA, is Chief Operating Officer / Chief Medical Officer of Midatech Pharma PLC. Dr Cook has more than 15 years of international experience in the pharma, biomedical and high technology sectors including roles across a range of therapeutic areas, such as neurology, inflammatory, immunology, and endocrine, covering both drug development and medical affairs. He has established and led several healthcare initiatives including SpaceCode Healthcare Technologies, Sedation Solutions, and SwissCare Health care provider. Previous appointments also include senior positions at Serono Biotech, Novartis Pharma, Eli Lilly and Johnson & Johnson. Dr Cook is lead adviser for Ippon Capital SA’s life sciences practice. He is a qualified physician, has a B.Sc. in Pharmacology, Diploma in Anaesthesiology, and M.B.A. from the London Business School. He joined Midatech in 2014 after leading and concluding the Ippon Capital investment round.

Daniel Palmer

Dr. Daniel David Palmer is, Ph.D, MBA is Chief Scientific Officer of Midatech Pharma PLC. Dr Palmer is a chartered chemist and cross-disciplinary scientist, specialising in polymer science and fluidics for drug-delivery. He is an executive manager and innovator, with more than 10 years of industrial experience in building and leading research and development programmes, teams and relationships. He is also responsible for intellectual property strategy and management. Dr Palmer currently holds four degrees, including a PhD and an MBA.

Justin Barry

Justin Barry, BSc (Hons.), MBIOL, CBIOL, QP is Head - Manufacturing of Midatech Pharma PLC. Mr. Barry is a biopharmaceutical industry executive with over 30 years of experience in setting up and leading manufacturing and quality operations. Prior to joining Midatech, he led the Spanish operations for Genentech where he first held the position of Quality Director before being appointed General Manager, performing a pivotal role in the construction and set up of a new manufacturing facility for AvastinR, one of the most successful biological drugs to date. Before that Mr Barry set up manufacturing facilities for the Wellcome Foundation and GlaxoSmithKline in Europe and the USA. At GlaxoSmithKline he also held executive positions in quality control and quality assurance. Mr Barry is a Chartered Biologist and a Member of the Society of Biology. He is also a registered European Qualified Person.

Tim Sparey

Dr. Tim Sparey, Ph.D. is Chief Business Officer of Midatech Pharma PLC. He has almost 20 years of experience in the pharmaceutical and biotech industries. He joined Q Chip as CEO in 2012 from Proximagen Group PLC where he was Head of Business Development for 3 years, following its acquisition by US Pharmaceuticals company Upsher Smith Laboratories. He previously held director level positions in Licensing & Business Development and R&D at Merck Serono and Merck & Co. Dr Sparey started his career with Merck & Co in neuroscience R&D following the completion of his PhD at the University of Warwick in 1995.

Simon De Vries

Dr. Simon (Sijmen) De Vries is Non-Executive Director of Midatech Pharma PLC. Dr. de Vries has extensive senior level experience in both the pharmaceutical and biotechnology industry. He is currently chief executive officer and chief financial officer of Pharming Group N.V., the Euronext-listed pharmaceutical company. Dr. de Vries was previously chief executive officer of both Switzerland-based 4-Antibody and Morphochem AG, and prior to this he worked at Novartis Pharma, Novartis Ophthalmics and at SmithKline Beecham Pharmaceuticals Plc, where he held senior business and commercial positions. Dr. de Vries holds an MD degree from the University of Amsterdam and a MBA in General Management from Ashridge Management College (UK).

John Johnston

Mr. John Joseph Johnston is Non-Executive Director of Midatech Pharma PLC. Mr Johnston is currently non-executive director of Flowgroup plc, Action Hotels and prior to this, was managing director of Institutional Sales at Nomura Code. He was previously director of Sales and Trading at Seymour Pierce from 2008 to 2011. In 2003, Mr. Johnston founded Revera Asset Management, where he oversaw an investment trust, a unit trust and a hedge fund, which he ran until 2007. From 1992 to 1997, Mr. Johnston was Head of Small Companies at Scottish Amicable, before spending a year at Ivory and Sime, again as Head of Small Companies from 1997 to 1998. He joined Legg Mason Investors for three years as Director of Small Companies Technology and Venture Capital Trusts, from 2000 to 2003, having previously spent two years as Head of Small Companies with Murray Johnstone. Mr. Johnston began his investment career at the Royal Bank of Scotland in 1981, working in the Trustee and Investment department, before moving to General Accident in 1985, holding the position of Head of Retail Funds before his move to Scottish Amicable.

Michele Luzi

Mr. Michele Luzi is Non-Executive Director of Midatech Pharma PLC. Mr Luzi is a partner in Bain & Company, based in the London office. He has recently led Bain’s EMEA Telecommunications Technology Media Practice for seven years and he was a board director of Bain & Company Global between 2006 and 2009. He has been a member of the World Economic Forum Global Agenda Council and of the Web Foundation Advisory Board. Prior to joining Bain & Company, Mr. Luzi worked in international management positions with Pirelli and also worked in Agusta and with the Italian Trade Commission. Mr. Luzi earned his MBA from INSEAD and graduated in Economics, with Honours, from the University of Rome.

Paul Protopapas

Mr. Paul (Pavlo) Protopapas is Non-Executive Director of Midatech Pharma PLC. Mr. Protopapa is the founder and managing partner of Ippon Capital, a private equity company based in Geneva, Switzerland. He is the chairman and chief executive officer of Spacecode Holdings, a technology provider in Healthcare & Luxury Goods, which he founded in 2005. He also serves as a non-executive director and lead investor of Socure Inc, a SaaS-based internet security company operating out of New York, USA. Pavlo has a Bachelor of Commerce (accounting, economics and commercial law) and Bachelor of Accounting Science (accounting) from the University of the Witwatersrand and the University of South Africa, respectively. He completed his articles at KPMG in Johannesburg, South Africa and has more than 15 years of experience in international commerce as chief financial officer of the Steinmetz Diamond Group from 1997 to 2012.

Simon Turton

Dr. Simon Turton, Ph.D, MBA, is Senior Independent Non-executive Director of Midatech Pharma PLC. Dr. Turton previously headed Warburg Pincus’ healthcare investing activities in Europe and was a principal at Index Ventures in Geneva. He has over 10 years of experience investing in biopharma companies following a ten year career in the international pharmaceutical industry incorporating research, business development and general management. Dr. Turton has an MBA from INSEAD and a Ph.D. in pharmacy from the University of London. He has been a board director of Archimedes Pharma, Eurand, ProStrakan and Tornier. Dr. Turton was most recently chairman of Q Chip and OpsiRx Pharmaceuticals prior to their acquisition by the Group.